Novo Nordisk A/S (NOVA STU) stock market data APIs
€41.1102
0.07(0.2%)
as of February 11, 2026
Try our APIs with
free plan!
Novo Nordisk A/S Financial Data Overview
Price chart is built with
Anychart
Prev. Close
41.1102
Open
41.1829
High
41.2356
Low
40.2215
52 wk Range
36.5-88.0431
Market Cap
230 198 M
Dividends (Yield)
0.0219
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Novo Nordisk A/S data using free add-ons & libraries
Get Novo Nordisk A/S Fundamental Data
Novo Nordisk A/S Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-02-04
- EPS/Forecast: 5.9
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Novo Nordisk A/S News
New
Novo Nordisk Pops After Leapfrogging Eli Lilly With An Obesity Pill
Novo Nordisk stock popped Tuesday on reports it's asked the FDA to approve its weight-loss pill, an oral version of Wegovy. Continue Reading View Comments
Eli Lilly jumps as results from weight-loss pill study rival competitor’s
Shares of Eli Lilly (LLY) jumped on Thursday morning after the company announced topline Phase 3 results from ACHIEVE-1, evaluating the safety and efficacy of orforglipron compared to placebo in adult...
How Eli Lilly's GLP-1 pill could transform the weight-loss space
Eli Lilly surged during Thursday's trading session after promising test results came out of the pharmaceutical company's ongoing weight-loss pill trial. Bernstein US biopharmaceuticals senior analyst ...
Eli Lilly stock soars on positive weight-loss pill results
Eli Lilly (LLY) stock surges after releasing promising test results from the company's GLP-1 pill, which would serve as an alternative to injectable weight-loss drugs. Novo Nordisk (NVO) and Hims & He...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
